Evidence map›Paper›PMID 32002645›Full record

ArticleEuropean radiology2020

A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI.

Wentao Wang, Dongsheng Gu, Jingwei Wei, Ying Ding, Li Yang, Kai Zhu, Rongkui Luo, Sheng-Xiang Rao, Jie Tian, Mengsu Zeng

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Prediction of Histopathological Grade of Hepatocellular Carcinoma by Gadoxetic Acid-Enhanced Magnetic Resonance Imaging Radiomics Features.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Wentao WangDepartment of Radiology, Zhongshan Hospital, and Shanghai Medical Imaging Institute, Fudan University, 180 Fenglin Rd, Shanghai, 200032, China.
Dongsheng GuKey Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, 95 Zhongguancun East Road, Beijing, 100190, China.
Jingwei WeiKey Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, 95 Zhongguancun East Road, Beijing, 100190, China.
Ying DingDepartment of Radiology, Zhongshan Hospital, and Shanghai Medical Imaging Institute, Fudan University, 180 Fenglin Rd, Shanghai, 200032, China.
Li YangDepartment of Radiology, Zhongshan Hospital, and Shanghai Medical Imaging Institute, Fudan University, 180 Fenglin Rd, Shanghai, 200032, China.
Kai ZhuLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Rongkui LuoDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Sheng-Xiang RaoDepartment of Radiology, Zhongshan Hospital, and Shanghai Medical Imaging Institute, Fudan University, 180 Fenglin Rd, Shanghai, 200032, China.
Jie TianKey Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, 95 Zhongguancun East Road, Beijing, 100190, China. tian@ieee.org.
Mengsu ZengDepartment of Radiology, Zhongshan Hospital, and Shanghai Medical Imaging Institute, Fudan University, 180 Fenglin Rd, Shanghai, 200032, China. zengmengsu@outlook.com.ORCID http://orcid.org/0000-0001-6054-0824
Shanghai Medical College of Fudan University · CNChinese Academy of Sciences · CNFudan University · CNSun Yat-sen University · CNXidian University · CN

Funding

Chinese Academy of Sciences GJJSTD20170004National Natural Science Foundation of China 81227901National Natural Science Foundation of China 81527805National Natural Science Foundation of China 81571661the Shanghai Sailing Program 19YF1408100
6 · The paper itself

Abstract

objectivesWe aimed to develop a radiomics-based model derived from gadoxetic acid-enhanced MR images to preoperatively identify cytokeratin (CK) 19 status of hepatocellular carcinoma (HCC).

methodsA cohort of 227 patients with single HCC was classified into a training set (n = 159) and a time-independent validated set (n = 68). A total of 647 radiomic features were extracted from multi-sequence MR images. The least absolute shrinkage and selection operator regression and decision tree methods were utilized for feature selection and radiomics signature construction. A multivariable logistic regression model incorporating clinico-radiological features and the fusion radiomics signature was built for prediction of CK19 status by evaluating area under curve (AUC).

resultsIn the whole cohort, 57 patients were CK19 positive and 170 patients were CK19 negative. By combining 11 and 6 radiomic features extracted in arterial phase and hepatobiliary phase images, respectively, a fusion radiomics signature achieved AUCs of 0.951 and 0.822 in training and validation datasets. The final combined model integrated a-fetoprotein levels, arterial rim enhancement pattern, irregular tumor margin, and the fusion radiomics signature, with a sensitivity of 0.818 and specificity of 0.974 in the training cohort and that of 0.769 and 0.818 in the validated cohort. The nomogram based on the combined model showed satisfactory prediction performance in training (C-index 0.959) and validation (C-index 0.846) dataset.

conclusionsThe combined model based on a fusion radiomics signature derived from arterial and hepatobiliary phase images of gadoxetic acid-enhanced MRI can be a reliable biomarker for CK19 status of HCC. KEY POINTS: • Arterial rim enhancement pattern and irregular tumor margin on hepatobiliary phase on gadoxetic acid-enhanced MRI can be useful for evaluating CK19 status of HCC. • A radiomics-based model performed better than the clinico-radiological model both in training and validation datasets for predicting CK19 status of HCC. • The nomogram based on the fusion radiomics signature can be easily used for CK19 stratification of HCC.

Indexed as

Contrast MediaGadolinium DTPAAdultAgedAged, 80 and overArea Under CurveBiomarkersCarcinoma, HepatocellularFemaleHumansImage EnhancementKeratin-19Liver NeoplasmsLogistic ModelsMagnetic Resonance ImagingMaleBiomarkersContrast MediaGadolinium DTPAgadolinium ethoxybenzyl DTPAKeratin-19KRT19 protein, humanCytokeratin 19DiagnosisHepatocellular carcinoma

Identifiers

PMID32002645
OpenAlexW3003971151

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.